Biohaven Research ISIN: VGG1110E1079

Biohaven (NYSE: BHVN) presented Phase 1 data for BHV-1510, a next‑generation Trop2 antibody‑drug conjugate, in combination with Regeneron’s anti‑PD‑1 cemiplimab at ESMO IO (Dec 10–12, 2025). At the 2.5 mg/kg Q3W BHV‑1510 dose, confirmed objective response rate (ORR) was 72.7% with confirmed responses including 3/5 NSCLC (60%), 4/4 endometrial cancer (100%, including a CR) and 1/2 urothelial (50%). Across 23 efficacy‑evaluable participants the confirmed ORR was 52.2%. Median time to response was 11.1 weeks. Safety showed low rates of payload‑related toxicities, no interstitial lung disease, no treatment discontinuations for AEs, and a favorable PK with unconjugated payload payload‑to‑ADC molar ratio <1%.

Bleibt stark

Ich bin drin. Also investiert meinte ich

Hoffentlich halten heute die 15

Der Aufwärtstrend hat begonnen

Und aufwärts geht es 👍

Was eine nachkaufen Gelegenheit

🥰

Heute 1.pos geöffnet. Im janus henderson Fond biotechnology aktuell vorhanden. Ich liebe dieses Manager immer ein gutes Gespür für aktien.